s-1-(combination) has been researched along with Pleurisy* in 2 studies
1 review(s) available for s-1-(combination) and Pleurisy
Article | Year |
---|---|
[An autopsy of G-CSF-producing anaplastic carcinoma of the pancreas with impaired accumulation on FDG-PET after S-1 chemotherapy].
This paper presents a woman in her 70's with G-CSF producing anaplastic carcinoma of the pancreas(Stage IVb)who underwent chemotherapy by S-1 alone. On FDG-PET after the first course, accumulation of FDG was impaired remarkably. After the second course, the patient died of carcinomatous pleuritis and peritonitis on the 88th day after initiation of treatment. G-CSF producing anaplastic carcinoma of the pancreas is extremely rare and there are no reports with regard to response evaluation by FDG-PET. Thus, this case has significant clinical value. Topics: Aged; Antimetabolites, Antineoplastic; Autopsy; Carcinoma; Drug Combinations; Fatal Outcome; Female; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Oxonic Acid; Pancreatic Neoplasms; Pleurisy; Positron-Emission Tomography; Tegafur | 2013 |
1 other study(ies) available for s-1-(combination) and Pleurisy
Article | Year |
---|---|
[A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].
A 71-year-old man underwent right hemicolectomy for an ascending colon cancer (stage II, Cur A) in September 2001. Adjuvant chemotherapy with tegafur/uracil was performed, but CT scans and FDG-PET, conducted in May 2003, revealed cancerous pleuritis and lung metastasis. Although 2 courses of the chemotherapy with LV+5-FU (RPMI regimen) were completed, progressive disease was confirmed. Therefore, the chemotherapy with CPT-11 (100 mg/ day; day 1, 15)+S-1 (100 mg/day; day 1-21) was started in May 2004. After completion of 6 courses, CT scan showed a partial response. Only grade 2 vomiting was noted as an adverse reaction to the treatment, however, the patient has been managed on an outpatient basis for the last 3 years with good QOL and the cancer under control. This case suggests that this combination therapy can be expected to be highly effective as a safe approach for continuously maintaining the QOL of patients with advanced or recurrent colorectal cancer. Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pleurisy; Positron-Emission Tomography; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |